NCT07577505Recruiting
Histidine Supplementation for Antitumor Immunity in Colorectal Cancer
A Single-arm Clinical Study of Histidine Supplementation for Antitumor Immunity in Colorectal Cancer
Source: ClinicalTrials.gov · Last updated 20 Aug 2026
Brief summary (registry, in English)
The goal of this clinical study is to learn whether oral histidine supplementation may be safely used to support antitumor immune function during standard colorectal cancer treatment. Participants with colorectal cancer in the supplementation group will: Take 2g oral histidine once daily during standard colorectal cancer treatment; Provide blood samples before and after supplementation; Attend regular follow-up visits for laboratory tests, safety assessment, and treatment evaluation.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 24 Apr 2026
- Start date
- 6 May 2026
- Primary completion date
- Dec 2026
- Lead sponsor
- Jing-yuan Fang, MD, Ph. D
- Diseases
- Colorectal cancer
- NCT number
- NCT07577505
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 6 May 2026 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in other interventional clinical trials (including drugs, nutritional supplements, medical devices, etc.) within 4 weeks prior to enrollment.
Other illness
- Presence of ascites, severe diarrhea, intractable vomiting, severe malabsorption syndrome, paralysis, mechanical intestinal obstruction, or active gastrointestinal bleeding.
- Allergy to sample components.
- Presence of cognitive impairments or mental illnesses that prevent understanding of the study procedures.
- Presence of any other conditions, judged by the researcher, make the participant unsuitable for participation in the study.
Other
- Current use of other nutritional supplements that may affect the validity and effectiveness of the study results.
- Pregnant, lactating female patients or women with fertility who test positive in the baseline pregnancy test.
Who the study is looking for
- Patients aged 18-80 years, regardless of sex.
- Body mass index (BMI) ≥18.5.
- NRS-2002 score \<3.
- Diagnosed with stage II or higher colorectal cancer who require pharmacological intervention.
- Capable of oral intake of medication.
- Willing to participate in the study and provide written informed consent.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Punan Hospital of Pudong New District Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.